Venous thromboembolism and bleeding in advanced melanoma: a propensity-matched cohort analysis comparing first-line immunotherapy and targeted therapy

Furkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E Drews, Rushad Patell · 2026

Read Venous thromboembolism and bleeding in advanced melanoma: a propensity-matched cohort analysis comparing first-line immunotherapy and targeted therapy by Furkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E Drews, Rushad Patell (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13508621.txt.

Description

Furkan Bahar and five co-authors compare clotting and bleeding risks between the two first-line drug routes for advanced melanoma, in 2026 work. Vein clots are a leading cause of illness in cancer patients, and both immune therapy pairs and targeted tablet pairs are standard openers. Adults starting either the immune pair or the targeted pair were matched one to one on background traits, giving 1,043 patients per group. Clots, bleeding, and death were tracked for six months.

The immune pair carried clearly higher clot risk: seven percent against about four percent in six months. Lung clots and leg vein clots each ran higher too. Bleeding, including brain and gut bleeding, did not differ between the groups. Deaths ran slightly higher with the immune pair, though that gap missed statistical firmness. They suggest clot prevention planning should weigh which melanoma opener a patient receives.

Catalog record

CREATORFurkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E Drews, Rushad Patell
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13508621

Browse the full library · About the Tower of Babel